GelMEDIX
Develops regenerative therapies to restore vision by regenerating damaged retinal cells
$13MSeed
Role not disclosedSP
Safar Partners
Activity from announced rounds
Activity in this selectionUnited States · Feb 28, 2026 · Feb 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $46M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionAlva Energy
Developer of standardized upgrades that increase output from existing nuclear power plants.
$33MSeries A
Role not disclosed